Which is better, semaglutide or setmelanotide?
For common obesity, semaglutide is approved, more effective on average, has cardiovascular outcomes evidence, and comes as a weekly injection or daily tablet, while setmelanotide is not indicated. For a confirmed genetic defect in the melanocortin pathway or hypothalamic obesity, setmelanotide acts downstream of the defect and is the drug labeled for that cause. They have never been compared directly. [1] [2] [3] [4] [5] [6]
How do semaglutide and setmelanotide compare?
| Dimension | Semaglutide | Setmelanotide |
|---|---|---|
| Who it is for [3] [4] [6] [7] | Wegovy: chronic weight management in adults and adolescents 12 and older, cardiovascular risk reduction, and MASH with fibrosis. Ozempic and Rybelsus: type 2 diabetes. | Imcivree: chronic weight management in obesity due to POMC, PCSK1, or LEPR deficiency (2020) or Bardet-Biedl syndrome (2022), extended to age 2 and older in December 2024, and acquired hypothalamic obesity in patients 4 and older (March 2026). Not indicated for common obesity. |
| Mechanism [3] [4] | GLP-1 receptor agonist. | Melanocortin-4 receptor agonist acting in the hypothalamus. |
| Weight loss evidence [1] [5] [8] | 14.9% versus 2.4% on placebo at 68 weeks (STEP 1, 1,961 adults). | Bardet-Biedl syndrome: 32% of patients 12 and older lost at least 10% at 52 weeks; POMC or PCSK1 deficiency: 80% lost at least 10% at one year. |
| Cardiovascular outcomes [2] [4] | SELECT: 20% relative reduction in major adverse cardiovascular events (hazard ratio 0.80). | No cardiovascular outcomes trial; not studied for this purpose. |
| Side effects [1] [3] [4] | Nausea 44%, diarrhea 32%, vomiting 24% in STEP 1; thyroid C-cell boxed warning; gallbladder disease. | Injection site reactions, hyperpigmentation, nausea, spontaneous erections; label warning about depression and suicidal ideation. |
| Route and frequency [3] [4] | Once weekly injection or once daily tablet. | Once daily injection. |
| Regulatory status [3] [4] [6] [9] | FDA approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021). Shortage-based compounding ended in 2025. | FDA approved (Imcivree 2020, expanded to acquired hypothalamic obesity in March 2026). Not a compounding candidate. |
| WADA status [10] | Not on the WADA Prohibited List. | Not on the WADA Prohibited List. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Semaglutide | Setmelanotide |
|---|---|---|
| Class | GLP-1 receptor agonist (31 amino acid analog of human GLP-1, acylated for once weekly dosing) | Cyclic 8 amino acid melanocortin-4 receptor (MC4R) agonist |
| What it is | FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit. | FDA approved hunger-pathway (MC4R) drug for rare genetic obesity (POMC, PCSK1, LEPR, Bardet-Biedl) and acquired hypothalamic obesity; not for common obesity. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: FDA approved | Regulatory: FDA approved |
| Compounding | FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms. | FDA approved product (Imcivree, November 2020 for POMC, PCSK1, and LEPR deficiency obesity; June 2022 for Bardet-Biedl syndrome; December 2024 expansion to ages 2 and older). It is available only by prescription and requires a confirmed genetic diagnosis for coverage. Because an approved product exists and is not in shortage, compounding is not permitted except for a documented patient specific clinical need. Setmelanotide is not on any FDA compounding bulks list. The current label also covers acquired hypothalamic obesity in patients 4 years and older. |
| WADA | WADA: Not WADA prohibited | WADA: Not WADA prohibited |
| Routes | Subcutaneous injection once weekly (Ozempic, Wegovy), Oral tablet once daily (Wegovy tablets, Ozempic tablets, Rybelsus) | Subcutaneous injection once daily |
| Typical cost | Manufacturer list price is 1,349.02 USD per month for Wegovy and 1,027.51 USD for Ozempic (checked 2026-09-22), falling to 675 USD for both on January 1, 2027. Manufacturer self-pay prices run 149 to 499 USD per month by product and dose, with the Wegovy pen at 349 USD. With commercial insurance the manufacturer savings offer can bring a covered prescription to 25 USD per month, and eligible Medicare Part D enrollees pay 50 USD per month for Wegovy under the Medicare GLP-1 Bridge (July 2026 to December 2027). A 2024 study found compounded semaglutide at a median 231 USD for the first month during the shortage; compounding is now limited to patient specific needs. | List price is in the hundreds of thousands of USD per year. Patients with a confirmed qualifying genetic diagnosis are usually covered by insurance with manufacturer support programs; out of pocket cost without coverage is prohibitive. |
| Last verified |
Has semaglutide been tested directly against setmelanotide?
No published trial has compared semaglutide and setmelanotide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do semaglutide and setmelanotide cost?
| Dimension | Semaglutide | Setmelanotide |
|---|---|---|
| Typical cost | $149 to $1,349 per month | List price is in the hundreds of thousands of USD per year. Patients with a confirmed qualifying genetic diagnosis are usually covered by insurance with manufacturer support programs; out of pocket cost without coverage is prohibitive. |
| Price detail | Semaglutide price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Frequently asked questions
Should someone with a POMC or LEPR mutation take semaglutide or setmelanotide?
Setmelanotide is the drug approved for obesity caused by POMC, PCSK1, or LEPR deficiency; in phase 3, 80% of POMC deficient patients lost at least 10% of body weight. Semaglutide has not been studied specifically in these conditions, so the choice belongs to a specialist. [4] [5]
Is setmelanotide a stronger weight loss drug than semaglutide?
Not for common obesity, where it is not indicated. Its large effects are in people whose obesity is caused by a defect in the melanocortin pathway. [4] [5]
Does either one come as a pill?
Semaglutide does, as a once daily tablet for type 2 diabetes and for weight management. Setmelanotide is only a daily injection. [3] [4] [7]
What is acquired hypothalamic obesity and which drug is approved for it?
It is rapid weight gain after damage to the hypothalamus, for example from a tumor or its treatment. In March 2026 FDA approved setmelanotide for it in patients 4 and older; semaglutide is not labeled for it. [3] [6]
Conditions studied
From the blog
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021 (STEP 1)PubMed 33567185, 2021
- [2]Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023 (SELECT)PubMed 37952131, 2023
- [3]FDA prescribing information for Wegovy (semaglutide) injection, via DailyMedFDA
- [4]FDA prescribing information for Imcivree (setmelanotide) injection, via DailyMedFDA
- [5]Clement K et al. Efficacy and safety of setmelanotide in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 2020PubMed 33137293, 2020
- [6]Trade press report: FDA approves setmelanotide for acquired hypothalamic obesity in patients 4 and older (March 19, 2026), accessed 2026-09-222026
- [7]FDA prescribing information for Ozempic (semaglutide) injection, via DailyMedFDA
- [8]Haqq AM et al. Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alstrom syndrome: phase 3 trial. Lancet Diabetes Endocrinol 2022PubMed 36356613, 2022
- [9]FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage resolution and compounding end dates)FDA
- [10]WADA Prohibited List (section S0 covers substances not approved by any government health authority)WADA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Semaglutide vs setmelanotide: evidence, cost, and legality. https://peptideagent.ai/compare/semaglutide-vs-setmelanotide- HTML link
<a href="https://peptideagent.ai/compare/semaglutide-vs-setmelanotide">Semaglutide vs setmelanotide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.